NEUROBO PHARMACEUTICALS, INC. Financials NeuroBo Pharmaceuticals, Inc.
Equities
NRBO
US64132R4048
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.605 USD | -2.05% |
|
+17.80% | -2.49% |
| Apr. 17 | Sector Update: Health Care Stocks Mixed Wednesday Afternoon | MT |
| Apr. 17 | NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 136.8 | 86.24 | 32.44 | 13.61 | 17.93 | 18.05 | - | - |
| Enterprise Value (EV) 1 | 136.8 | 86.24 | 32.44 | 13.61 | 17.93 | 18.05 | 18.05 | 18.05 |
| P/E ratio | -2.14 x | -2.87 x | -1.85 x | -0.13 x | -1.5 x | -1.05 x | -1.66 x | -1.84 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | -1,162,263 x | - | - | - | - |
| FCF Yield | - | - | - | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 65.1 | 68.4 | 111 | 2,372 | 4,852 | 4,906 | - | - |
| Reference price 2 | 2,100 | 1,260 | 292.8 | 5.740 | 3.697 | 3.680 | 3.680 | 3.680 |
| Announcement Date | 3/30/20 | 4/15/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.18 | -29.72 | - | -19.63 | -15.89 | -26.23 | -30.18 | -34.31 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.31 | -29.68 | - | -13.97 | -12.47 | -25.96 | -29.94 | -34.03 |
| Net income 1 | -21.31 | -29.68 | -15.28 | -13.97 | -12.47 | -25.96 | -29.94 | -34.03 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -979.2 | -439.2 | -158.4 | -43.44 | -2.460 | -3.500 | -2.220 | -2.005 |
| Free Cash Flow | - | - | - | -11.71 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 4/15/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.464 | - | -10.43 | -2.52 | -3.806 | -3.893 | -5.667 | -5.665 | -6.176 | -6.832 | -7.552 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -3.461 | - | -4.676 | -2.604 | -0.734 | -3.818 | -5.314 | -5.609 | -6.136 | -6.735 | -7.476 |
| Net income 1 | -3.461 | -3.113 | -4.676 | -2.604 | -0.734 | -3.818 | -5.314 | -5.609 | -6.136 | -6.735 | -7.476 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -38.40 | -28.00 | - | -0.4800 | -0.1600 | -0.7200 | -2.280 | -1.100 | -0.8450 | -0.7650 | -0.8000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 11/14/22 | 3/30/23 | 5/12/23 | 8/9/23 | 11/13/23 | 3/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | -11.7 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 4/15/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.68
USD
Average target price
36.5
USD
Spread / Average Target
+891.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.49% | 18.05M | |
| -0.86% | 104B | |
| +6.54% | 97.47B | |
| +5.71% | 22.25B | |
| -12.80% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.08% | 16.36B | |
| +8.38% | 14.39B | |
| +38.93% | 12.37B |
- Stock Market
- Equities
- NRBO Stock
- Financials NeuroBo Pharmaceuticals, Inc.
